The Company''s 33rd AGM was held today and the business mentioned in the Notice dated July 16, 2025 was transacted.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem held its 33rd AGM on September 25, 2025 via video conferencing, attended by 38 members. The Chairman shared FY25 highlights: revenue rose to Rs. 285.86 Crores from Rs. 281.86 Crores, while EBIDTA jumped sharply to Rs. 11.21 Crores from Rs. 3.85 Crores in the prior year. The Company spent about Rs. 0.66 Crore on capex during the year and plans to add new products to its existing range, with future expansion expected to serve both local manufacturers and export demand. The Statutory Auditor's report was unqualified, while the Secretarial Auditor's report carried qualifications.
Strong EBIDDA growth signals improved profitability, and the declared dividend plus product expansion plans are positive for shareholders. The qualified Secretarial Audit report is a minor governance red flag worth tracking, though no specific concern was highlighted.